Clarithromycin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Clarithromycin | 250-500mg PO Q24H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 748 | 20-30 | 2.3-6 | 22 | 70 | 2-4 | N/A | N/A |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Chu S, Sennello L, Bunnell S, Varga L, Wilson D, Sonders C. Pharmacokinetics of Clarithromycin, a New Macrolide, after Single Ascending Oral Doses. Antimicrobial agents and chemotherapy 1992; 36(11), 2447-53.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01211
- Lamm J, Quigley S, Sanders S, Cavanaugh J. Metabolism and Disposition of Clarithromycin in Man. Drug Metabolism and Disposition 1990; 18(4), 441-446.